Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.935 USD | +0.36% | -5.83% | -20.57% |
05/06 | Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating | MT |
04/06 | FDA panel to review psychedelic drug MDMA for first time | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.57% | 47Cr | |
+53.31% | 5.93TCr | |
+41.42% | 4.09TCr | |
-5.42% | 4.02TCr | |
-5.16% | 2.87TCr | |
+12.68% | 2.66TCr | |
-20.76% | 1.89TCr | |
+30.75% | 1.25TCr | |
+0.26% | 1.24TCr | |
+26.24% | 1.23TCr |
- Stock Market
- Equities
- CMPS Stock
- News COMPASS Pathways plc
- Oppenheimer Adjusts COMPASS Pathways Price Target to $33 From $55, Maintains Outperform Rating